EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is entered into effective as of July 1, 2020 (the “Effective Date”), by and between Mereo BioPharma Group plc, a company incorporated in England and Wales (the “Company”) and John Lewicki, Ph.D. (“Executive” and, together with the Company, the “Parties”).
THIS CONTRACT OF EMPLOYMENT dated October 20, 2020 is madeMereo Biopharma Group PLC • March 31st, 2021 • Pharmaceutical preparations • England
This Contract sets out the terms and conditions of your employment with the Company at the date of this Contract and supersedes all previous arrangements or agreements whether oral or in writing between you and the Company in relation to the matters dealt with in it.
DEED OF CONSENT AND AMENDMENT TO WARRANT INSTRUMENTDeposit Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations
ContractDeposit Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations • England and Wales
THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR PURSUANT TO AN APPLICABLE EXEMPTION THEREFROM.
DEED OF CONSENT AND AMENDMENT TO WARRANT INSTRUMENTWarrant Instrument • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED COLLABORATION AND LICENSE AGREEMENT by and between MEREO...Collaboration and License Agreement • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This Collaboration and License Agreement (this “Agreement”) is entered into as of December 17, 2020 (the “Execution Date”) by and between Mereo BioPharma 3 Limited, a corporation with a place of business at 1 Cavendish Place, London, W1G 0QF, United Kingdom (“Mereo”) and Ultragenyx Pharmaceutical Inc., a corporation with a place of business at 60 Leveroni Court, Novato, CA 94949, United States (“UGNX”). UGNX and Mereo are each hereafter referred to individually as a “Party” and together as the “Parties”.
DEED OF CONSENT AND AMENDMENT TO NOTE INSTRUMENTNote Instrument • March 31st, 2021 • Mereo Biopharma Group PLC • Pharmaceutical preparations
